This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bates, S E Articles by Fojo, A T Search for Related Content PubMed PubMed Citation Articles by Bates, S E Articles by Fojo, A T

 Previous Article  |  Next Article 

Mol Cell Biol. 1989 October; 9(10): 4337-4344

Expression of a drug resistance gene in human neuroblastoma cell lines: modulation by retinoic acid-induced differentiation.

Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland 20892.

ABSTRACT

Expression of a multidrug resistance gene (mdr1) and its protein product, P-glycoprotein (Pgp), has been correlated with the onset of multidrug resistance in vitro in human cell lines selected for resistance to chemotherapeutic agents derived from natural products. Expression of this gene has also been observed in normal tissues and human tumors, including neuroblastoma. We therefore examined total RNA prepared from human neuroblastoma cell lines before and after differentiation with retinoic acid or sodium butyrate. An increase in the level of mdr1 mRNA was observed after retinoic acid treatment of four neuroblastoma cell lines, including the SK-N-SH cell line. Western blot (immunoblot) analysis demonstrated concomitant increases in Pgp. However, studies of 3H-vinblastine uptake failed to show a concomitant Pgp-mediated decrease in cytotoxic drug accumulation. To provide evidence that Pgp was localized on the cell surface, an immunotoxin conjugate directed against Pgp was added to cells before and after treatment with retinoic acid. Incorporation of [3H]leucine was decreased by the immunotoxin in the retinoic acid-treated cells compared with the undifferentiated cells. These results demonstrate that whereas expression of the mdr1 gene can be modulated by differentiating agents, increased levels of expression are not necessarily associated with increased cytotoxic drug accumulation.

This article has been cited by other articles:

• Kuwano, M., Oda, Y., Izumi, H., Yang, S.-J., Uchiumi, T., Iwamoto, Y., Toi, M., Fujii, T., Yamana, H., Kinoshita, H., Kamura, T., Tsuneyoshi, M., Yasumoto, K., Kohno, K. (2004). The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Molecular Cancer Therapeutics 3: 1485-1492 [Abstract] [Full Text]  
• Piekarz, R. L., Robey, R. W., Zhan, Z., Kayastha, G., Sayah, A., Abdeldaim, A. H., Torrico, S., Bates, S. E. (2004). T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103: 4636-4643 [Abstract] [Full Text]  
• Sandor, V., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R., Piekarz, R. L., Tucker, E., Figg, W. D., Chan, K. K., Goldspiel, B., Fojo, A. T., Balcerzak, S. P., Bates, S. E. (2002). Phase I Trial of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228, NSC 630176), in Patients with Refractory Neoplasms. Clin. Cancer Res. 8: 718-728 [Abstract] [Full Text]  
• Scotto, K. W., Johnson, R. A. (2001). Transcription of MDR1: A Therapeutic Target. Mol. Interv. 1: 117-125 [Abstract] [Full Text]  
• Maris, J. M., Matthay, K. K. (1999). Molecular Biology of Neuroblastoma. JCO 17: 2264-2264 [Abstract] [Full Text]  
• Dwivedi, R. S., Wang, L.-J., Mirkin, B. L. (1999). S-Adenosylmethionine Synthetase Is Overexpressed in Murine Neuroblastoma Cells Resistant to Nucleoside Analogue Inhibitors of S-Adenosylhomocysteine Hydrolase: A Novel Mechanism of Drug Resistance. Cancer Res. 59: 1852-1856 [Abstract] [Full Text]  
• Egashira, M., Kawamata, N., Sugimoto, K., Kaneko, T., Oshimi, K. (1999). P-Glycoprotein Expression on Normal and Abnormally Expanded Natural Killer Cells and Inhibition of P-Glycoprotein Function by Cyclosporin A and Its Analogue, PSC833. Blood 93: 599-606 [Abstract] [Full Text]  
• Nakayama, M., Wada, M., Harada, T., Nagayama, J., Kusaba, H., Ohshima, K., Kozuru, M., Komatsu, H., Ueda, R., Kuwano, M. (1998). Hypomethylation Status of CpG Sites at the Promoter Region and Overexpression of the Human MDR1 Gene in Acute Myeloid Leukemias. Blood 92: 4296-4307 [Abstract] [Full Text]  
• Thottassery, J. V., Zambetti, G. P., Arimori, K., Schuetz, E. G., Schuetz, J. D. (1997). p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc. Natl. Acad. Sci. USA 94: 11037-11042 [Abstract] [Full Text]  
• Torigoe, K, Sato, S, Kusaba, H, Kohno, K, Kuwano, M, Okumura, K, Green, E D, Tsui, L C, Scherer, S W, Schlessinger, D (1995). A YAC-based contig of 1.5 Mb spanning the human multidrug resistance gene region and delineating the amplification unit in three human multidrug-resistant cell lines.. Genome Res 5: 233-244 [Abstract]  
• Kusaba, H, Kohno, K, Asakuno, K, Kuwano, M, Okumura, K, Green, E D, Schlessinger, D, Wada, M (1995). Functional expression of yeast artificial chromosome-human multidrug resistance genes in mouse cells.. Genome Res 5: 245-258 [Abstract]  
• Vilaboa, N. E., Galan, A., Troyano, A., de Blas, E., Aller, P. (2000). Regulation of Multidrug Resistance 1 (MDR1)/P-glycoprotein Gene Expression and Activity by Heat-Shock Transcription Factor 1 (HSF1). J. Biol. Chem. 275: 24970-24976 [Abstract] [Full Text]